Monday, March 11, 2013

Celgene (CELG) up 7 of Last 8 Days (Core Equities folio Holding)

Celgene (CELG) added 56 cents to 111.92, hitting a new closing high for the seventh time in the past eight sessions. Celgene shows no signs of slowing down.

The drug maker relies on the cancer drug Revlimid for more than half of its revenue, but trials of a pancreatic cancer treatment, Abraxane, have also been positive.

Above excerpt from IBD's

Market Direction Model
Market in Confirmed Uptrend

This blog post does not constitute an offer of investment advice. This blog is only provided for educational purposes. Please read the Important Blog Disclosure posted in the right channel bar.

No comments:

Post a Comment